A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Clinical Trial ID NCT01227824

Rank	Title	Journal	Year	PubWeight™‹?›
1	Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.	Lancet	2013	3.92
2	Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.	Lancet Infect Dis	2013	2.65
3	Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.	AIDS	2015	0.91
4	Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.	Infect Dis Ther	2014	0.89
5	Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.	Clin Drug Investig	2015	0.86
6	Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.	Clin Med Rev Ther	2011	0.80
7	Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.	Infect Dis Ther	2015	0.75